Multidrug-Resistant Bacteria Induce Recurrent Keratoconjunctivitis in a Patient with Common Variable Immunodeficiency: Case Report and Literature ReviewChao, Jiang MMed; Yumei, Zhou MMed; Zhiqun, Wang MD; Yang, Zhang MD; Xuguang, Sun PhDCornea: November 2013 - Volume 32 - Issue - p S39–S42 doi: 10.1097/ICO.0b013e3182a2c7e6 Article Abstract Author Information Purpose: We present a case study regarding a patient with recurrent keratoconjunctivitis that presented as an initial manifestation of common variable immunodeficiency (CVID). Methods: We describe a case and review the recent relevant medical literature. Results: A 33-year-old male had recurrent keratoconjunctivitis induced by multidrug-resistant bacteria. Topical vancomycin treatment was effective, but infection recurred when the vancomycin treatment was stopped. The patient was transferred to the Department of Medicine to rule out potential systemic immune diseases and was finally diagnosed with CVID. Intravenous immunoglobulin (IVIG) was administered, and the patient was followed up monthly without any recurrence of infection to date. IVIG will be administered monthly for the patient's lifetime. Conclusions: Keratoconjunctivitis is a CVID-associated manifestation, sometimes appearing as the first presentation. CVID should be considered when unexplained recurrent conjunctival and/or corneal bacterial infections are observed. Topical therapy is not sufficient to treat this infection and IVIG is necessary. Beijing Ophthalmology & Visual Sciences Key Lab, Beijing Tongren Eye Center, Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital University of Medical Science, Beijing, China. Reprints: Sun Xuguang, 17 Hougou Alley, Chongnei St, Dongcheng District, Beijing 100005, China (e-mail: firstname.lastname@example.org). Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.corneajrnl.com). The authors have no funding or conflicts of interest to disclose. © 2013 by Lippincott Williams & Wilkins.